FDA 483 - BASF Corporation - May 29, 2025

An FDA inspection of BASF Corporation in East Setauket, NY, from May 27-29, 2025, revealed a significant deficiency in the firm's quality control. The company failed to establish and follow procedures for qualifying raw material suppliers and did not perform full confirmatory testing of incoming raw materials against certificates of analysis, potentially compromising the quality of their drug products.